Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 13/20 | 0.38 |
| ▸ | PPARA | Q07869 | 12/20 | 0.38 |
| ▸ | PPARD | Q03181 | 10/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4336608 | 0.86 | PPARG (0.42) | PPARGPPARAPPARDP2RX3KMT2A | |
| SCHEMBL4334577 | 0.85 | SCN9A (0.40) | PPARGPPARAPPARDKMT2AMEN1 | |
| SCHEMBL4327205 | 0.85 | ATM (0.42) | PPARGPPARAPPARDKMT2AMEN1 | |
| SCHEMBL4336600 | 0.85 | PPARG (0.41) | RECQLPPARGPPARAPPARD | |
| SCHEMBL4347011 | 0.84 | SMN1; SMN2 (0.39) | PPARGPPARAKMT2AMEN1 | |
| SCHEMBL4346189 | 0.84 | CYP1A2 (0.47) | PPARGPPARAPPARDKMT2AMEN1 | |
| SCHEMBL4343682 | 0.82 | PPARA (0.47) | PPARGPPARAPPARD | |
| SCHEMBL4335087 | 0.80 | KMT2A (0.41) | PPARGPPARAPPARDKMT2AMEN1 | |
| SCHEMBL13810649 | 0.80 | PPARG (0.39) | PPARGPPARAPPARD | |
| SCHEMBL4329917 | 0.80 | DNMT1 (0.40) | PPARGPPARAPPARDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | RECQL 1094/4885PPARG 379/4885PPARA 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.